ERBB2 and breast carcinoma: We identified thirty-three adults with metastatic HER2-positive breast cancer treated between March 2013 and July 2018 with T-DM1 either as subsequent therapy after progression on a pertuzumab-based regimen (i.e., “pertuzumab-pretreated”) or without prior exposure to pertuzumab (i.e., “pertuzumab-naïve”).